2025-11-16 - Analysis Report
Okay, here's a comprehensive analysis of Schrodinger Inc. (SDGR) based on the provided data.

**Report on Schrodinger Inc. (SDGR)**

Schrodinger Inc. is a company that develops software for drug discovery and materials science.

**1. Performance vs. S&P 500 (VOO)**

*   **Key Metrics:**
    *   SDGR Cumulative Return: -56.83%
    *   VOO Cumulative Return: 66.77%
    *   Absolute Divergence (Current): -118.4
    *   Relative Divergence: 1.7 (on a scale from min to max divergence)

*   **Analysis:** SDGR has significantly underperformed the S&P 500 (VOO) over the analyzed period. The current divergence is substantial, with the relative divergence indicating that SDGR is near its worst performance relative to the benchmark within the observed range.

*   **Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
| ---------- | ------- | ----- | ------- | ----- | ------ |
| 2020-2022  | -70.0%  | 78.2% | -76.0%  | 0.1   | 1.3    |
| 2021-2023  | -57.0%  | 81.0% | -59.0%  | -0.0  | 2.6    |
| 2022-2024  | 6.0%    | 81.0% | -14.0%  | -0.0  | 1.4    |
| 2023-2025  | -5.0%   | 82.6% | -68.0%  | -0.0  | 1.3    |

*   **Analysis:**
    *   **CAGR:** Consistently negative Compound Annual Growth Rate across most periods, indicating poor long-term growth.
    *   **MDD:** High Maximum Drawdown values suggest significant volatility and risk.
    *   **Alpha:** Negative Alpha consistently implies that the investment has underperformed its benchmark on a risk-adjusted basis.
    *   **Beta:** Beta values fluctuating around 0 indicate the stock's price is not highly correlated with the market. This means its movements are independent of the broader market trends.
    *   **Cap:** Market capitalization in billions, remaining relatively stable.

**2. Recent Price Action**

*   **Current Price:** \$17.64
*   **Previous Close:** \$17.20
*   **Change:** 2.56%
*   **Moving Averages:**
    *   5-day MA: \$17.88
    *   20-day MA: \$20.04
    *   60-day MA: \$19.78

*   **Analysis:** The stock has experienced a recent positive price change. However, the current price is still below the 5-day, 20-day, and 60-day moving averages, suggesting that the short-term trend might be weakening.

**3. Technical Indicators & Expected Return**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 20.24 (Oversold)
*   **PPO:** -1.90
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (47 shares - Very Safe - MRI:0.90) Monthly invest 1.4% of total investment (\$1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Delta_Previous_Relative_Divergence (20-day):** 1.1 (+) indicates a recent increase in relative performance.
*   **Expected Return:** -3643.7% (Significant negative expected return compared to S&P 500 over a 2+ year investment horizon)

*   **Analysis:**
    *   The RSI indicates that the stock is currently oversold, potentially suggesting a possible bounce or reversal.
    *   The PPO is negative, indicating that the short-term moving average is below the long-term moving average, which is generally a bearish signal.
    *   A recent upward movement of +2.56% may be caused by news or short covering.

**4. Recent News & Significant Events**

*   **[2025-11-10]**  Zacks: "Buy the Bottom" recommendation
*   **[2025-11-09]** Simply Wall St.: Questioning the right moment for Schrödinger after a price drop.
*   **[2025-11-07]** Insider Monkey: Milestone achievement for Neptune program.
*   **[2025-11-06]** Business Wire: Presentation at Jefferies London Healthcare Conference.
*   **[2025-11-06]** GuruFocus.com: Q3 Earnings Call Highlights - Revenue Surge & Strategic Shifts.
*   **[2025-11-05]** Zacks: Q3 Loss, but Tops Revenue Estimates.

*   **Analysis:**  The news is mixed. While there are some positive headlines about revenue and milestones, there are also concerns about the recent price drop and continued losses. Analyst ratings are generally positive.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean Rating: 1.67)
*   **Target Price:**
    *   Average: \$27.22
    *   High: \$33.00
    *   Low: \$18.00

*   **Analysis:** Analysts generally have a positive outlook on the stock, with a "Buy" consensus and a significant upside potential based on the average target price.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
| ---------- | ----- | --------- |
| 2025-11-05 | -0.45 | 0.05 B\$  |
| 2025-08-06 | -0.59 | 0.05 B\$  |
| 2025-05-07 | -0.82 | 0.06 B\$  |
| 2024-11-12 | -0.52 | 0.04 B\$  |
| 2025-11-05 | -0.52 | 0.04 B\$  |

*   **Analysis:** The company is consistently reporting losses per share (EPS). While revenue has fluctuated, it shows signs of marginal growth.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| ------------ | --------- | ------------- |
| 2025-09-30   | \$0.05B   | 51.61%        |
| 2025-06-30   | \$0.05B   | 47.77%        |
| 2025-03-31   | \$0.06B   | 52.26%        |
| 2024-12-31   | \$0.09B   | 72.61%        |
| 2024-09-30   | \$0.04B   | 50.24%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
| ------------ | --------- | --------- |
| 2025-09-30   | \$0.32B   | -10.21%   |
| 2025-06-30   | \$0.34B   | -12.59%   |
| 2025-03-31   | \$0.37B   | -16.01%   |
| 2024-12-31   | \$0.42B   | -9.54%    |
| 2024-09-30   | \$0.45B   | -8.49%    |

*   **Analysis:** Revenue has been variable, but profit margins are generally high. However, the Return on Equity (ROE) is consistently negative, indicating that the company is not generating profits from shareholders' investments. Equity is decreasing over time.

**7. Overall Analysis**

Schrodinger Inc. (SDGR) presents a mixed picture.

*   **Negatives:**
    *   Significant underperformance compared to the S&P 500.
    *   High volatility.
    *   Consistently negative EPS and ROE.
    *   Negative expected return relative to the S&P 500 for long-term investment.
*   **Positives:**
    *   Positive analyst ratings with considerable upside potential.
    *   Recent positive price movement and oversold RSI indicating potential for a short-term bounce.
    *   High profit margins on revenue.
    *   Recent revenue beat estimates.
*   **Conclusion:**

While analysts are optimistic about the company's future, the current financial performance and negative expected returns suggest caution. The recent positive price movement and "Buy the Bottom" recommendations could be contrarian indicators for short-term gains, but a long-term investment appears risky based on the provided data. It would be prudent to conduct further research and due diligence before making any investment decisions.
